The AnticoagEvaluator App: A Little Help Choosing Appropriate Anticoagulation for Atrial Fibrillation

American College of Cardiology Foundation: June 27, 2013

At last! For patients and doctors weary of monitoring INRs, a new host of long-anticipated oral anticoagulant therapies have joined warfarin and aspirin as excellent options in reducing the associated risk of thromboembolic stroke in atrial fibrillation. But which option is best?
That, of course, depends on the patient. However, with more choices, decision-making can also be more complex.

The ACC’s AnticoagEvaluator application helps medical professionals make a fast and easy, evidence-based assessment of risks and benefits of our treatment options. The AnticoagEvaluator walks the user through the calculation of a CHADS2 and CHA2DS2-VASc score for a given patient, followed by a HAS-BLED bleeding risk score. The process takes less than a minute, and the app displays a detailed statistical analysis of your patient’s stroke and bleeding risk for every treatment option, including no therapy, aspirin alone, aspirin plus clopidogrel, warfarin, dabigatran, rivaroxaban, and apixaban! Read More